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ARTICLE
Genetic predisposition to hypertension is
associated with preeclampsia in European
and Central Asian women
Valgerdur Steinthorsdottir et al.#
Preeclampsia is a serious complication of pregnancy, affecting both maternal and fetal health.
In genome-wide association meta-analysis of European and Central Asian mothers, we
identify sequence variants that associate with preeclampsia in the maternal genome at
ZNF831/20q13 and FTO/16q12. These are previously established variants for blood pressure
(BP) and the FTO variant has also been associated with body mass index (BMI). Further
analysis of BP variants establishes that variants at MECOM/3q26, FGF5/4q21 and SH2B3/
12q24 also associate with preeclampsia through the maternal genome. We further show that
a polygenic risk score for hypertension associates with preeclampsia. However, comparison
with gestational hypertension indicates that additional factors modify the risk of
preeclampsia.
https://doi.org/10.1038/s41467-020-19733-6 OPEN
#A list of authors and their affiliations appears at the end of the paper.
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Between 10 and 15% of pregnant women develop new-onsethypertension after 20 weeks gestation1. Hypertensionaccompanied by proteinuria is known as preeclampsia,
which can progress into a serious disorder that contributes
worldwide to the death of an estimated 50,000 women and up to
1 million babies annually, making it one of the principal causes of
maternal and perinatal mortality2. Current models attribute
preeclampsia to a combination of maternal susceptibility, often
associated with an exaggerated inflammatory response to preg-
nancy and altered placental function with the release of stress
factors that trigger widespread activation of the maternal vascular
endothelium3. A familial predisposition to preeclampsia is well
documented4,5, and the evidence points to contributions from
both maternal and fetal genomes. We recently showed that the
fetal genome contains a preeclampsia susceptibility locus at
FLT16. However, previous attempts to identify maternal sequence
variants associated with preeclampsia through genome-wide
association scans (GWAS) or targeted gene-centric analysis
have been hampered by small sample size7–11.
Here we report the results of a meta-analysis of eight previously
unreported GWAS with 9515 preeclamptic women and 157,719
controls from Europe and Central Asia as well as an expansion of
our previous meta-analysis of preeclampsia offspring6. Maternal
and fetal mortality attributable to hypertensive pregnancy dis-
orders is higher in countries with developing maternity care sys-
tems, including those in Central Asia, an area that has been largely
neglected in genome-wide studies. We present whole-genome
sequences, and GWAS of maternal and fetal genomes, in data sets
from Uzbekistan and Kazakhstan, and find no evidence that the
genetic architecture of preeclampsia differs between the popula-
tions from Central Asia and those in Europe.
There is compelling epidemiological evidence that women with
hypertension during pregnancy, including preeclampsia, are at
increased risk of essential hypertension, coronary artery disease
(CAD), chronic renal disease, and type 2 diabetes (T2D) later in
life12. We have therefore explored our data using polygenic score
analysis of the correlation between preeclampsia and variants
associated with related phenotypes, including high BP, T2D,
CAD, and BMI.
In our discovery analysis, we find five variants associating with
preeclampsia through the maternal genome. All have previously
been associated with BP. We further show that genetic predis-
position to hypertension is a major risk factor for preeclampsia.
However, comparison with gestational hypertension implies that
additional factors are involved in the risk of preeclampsia.
Results
Association of fetal sequence variants with preeclampsia. We
evaluated the association of 12,130,433 sequence variants in indi-
viduals who were born of preeclamptic pregnancies (offspring) in
our combined meta-analysis of 4630 European cases and 373,345
controls and 2145 Central Asian cases and 2027 controls (Fig. 1a
and Supplementary Fig. 1). This corresponds to an effective sample
size of ~9323 cases and the same number of controls in the
combined analysis (Supplementary Fig. 2; see “Methods” section).
To facilitate the use of Central Asian data, we sequenced whole
genomes of 200 individuals from Kazakhstan and Uzbekistan
generating reference data to improve imputation (Supplementary
Table 1 and Supplementary Note 1). The association at the
reported FLT1 locus on 13q126 was strengthened in this analysis,
with a P-value of 3.0 × 10−11 and OR= 1.17 (95% CI: 1.12–1.23)
for the sentinel variant rs4769612 (Supplementary Table 2). This
variant is in linkage disequilibrium (LD) with the previously
reported rs4769613 (r2= 0.99). No other loci were associated at
genome-wide significance (defined here as P= 4 × 10−9 after
adjusting for the number of variants tested) in this data set
(Fig. 1a). In addition to the FLT1 locus, we followed up three
variants with P < 1 × 10−6 in the meta-analysis in additional
Kazakh samples (N= 452 cases, 361 controls). None of them
reached genome-wide significance in the combined analysis
(Supplementary Table 2). Follow-up genotyping in Finnish and
Kazakh data sets further validated the association of rs4769612
yielding a combined P-value 4.3 × 10−14 (Supplementary Table 2
and Supplementary Fig. 3). The conditional analysis identified a
second independent variant rs9508092 at the FLT1 locus (P= 3.0 ×
10−9 after conditioning on rs4769612) and confirmed another
previously reported6 independent signal at this locus rs71433277
(r2= 0.97 with previously reported rs12050029) (P= 6.6 × 10−6
after conditioning on rs4769612 and rs9508092) (Supplementary
Tables 3 and 4; Supplementary Fig. 4). Functional annotation of
these three independent signals shows that they all overlap reg-
ulatory regions in placental tissue of which one of the potential
target genes is FLT1 (Supplementary Data 1).
Association of maternal sequence variants with preeclampsia.
We evaluated the association of 11,796,347 sequence variants
with preeclampsia in our combined meta-analysis of 7219 Eur-
opean maternal cases and 155,660 controls and 2296 Central
Asian cases and 2059 controls (Fig. 1b and Supplementary Fig. 1).
This corresponds to an effective sample size of ~12,392 cases and
an equal number of controls in the combined analysis (Supple-
mentary Fig. 2 and see “Methods” section). The controls com-
prised women with healthy pregnancies, with the exception of the
two largest sample sets that used unselected (GOPEC) or female-
only (deCODE) population controls (Supplementary Table 1 and
see “Methods” section). One locus, on 16q12, reached genome-
wide significance (4 × 10−9) in the maternal meta-analysis
(Fig. 1b). We followed up the sentinel variants at this locus and 13
additional loci with P < 1 × 10−6 in additional samples of Eur-
opean and Kazakh origin (N= 2635 cases and 6379 controls)
(Supplementary Data 2). Combining the discovery and follow-up
data, rs1421085 in FTO (alpha-ketoglutarate-dependent dioxy-
genase) on 16q12 remained significant (P= 1.2 × 10−9,
OR= 1.11, 95% CI: 1.07–1.1.15) (Table 1 and Supplementary
Data 2). A second variant, rs259983 near ZNF831 (zinc finger
protein 831) on 20q13 also reached genome-wide significance
(P= 2.9 × 10−10, OR= 1.17, 95% CI: 1.11–1.23) (Table 1, Sup-
plementary Data 2 and Supplementary Fig. 4). We found no
evidence for heterogeneity in estimated effect size between the
European and Central Asian data for any of the follow-up var-
iants (Phet > 0.05, Supplementary Data 2). Results for individual
data sets are shown in Supplementary Fig. 3.
The two variants we identified as having a genome-wide
significant association with preeclampsia through the maternal
genome have both been reported to associate with BP in large
meta-analyses13,14. Furthermore, the risk allele at the FTO variant
rs1421085 associates with increased BMI, obesity, and a number
of other traits including T2D15.
Preeclampsia and BP variants. In addition to the FTO and
ZNF831 variants being in known BP loci, three more variants at
BP loci (MECOM/3q26, FGF5/4q21, and SH2B3/12q24) were
among the variants we followed up but that did not reach
genome-wide significance in the combined meta-analysis (P= 1.2
to 1.7 × 10−8) (Supplementary Data 2). Therefore, we evaluated
the preeclampsia association in our meta-analysis for each of the
896 established BP variants, as reported by Evangelou et al.16. The
most significant association was found for rs16998073, upstream
of FGF5, P= 8.8 × 10−8, followed by rs6015450 in ZNF831,
P= 4.8 × 10−7, rs3184504, a missense variant in SH2B3,
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P= 5.3 × 10−7 and rs419076 in MECOM P= 7.7 × 10−6 (Table 2
and Supplementary Data 3). These four associations are sig-
nificant after adjusting for the number of variants tested (P <
0.05/896= 5.6 × 10−5). We thus conclude that in addition to the
variants near ZNF831 and FTO that exhibited genome-wide sig-
nificance, BP variants at FGF5, SH3B2, and MECOM also
associate with preeclampsia.
The ZNF831 variants rs259983 and rs6015450, identified
through the preeclampsia meta-analysis and thorough testing of
BP variants, respectively, are in strong LD (r2= 0.74 in European
data; Supplementary Table 5). Furthermore, the variants at FGF5,
SH3B2, and MECOM that we followed up from our meta-analysis
are in LD with the corresponding proximal BP variants (Table 2
and Supplementary Data 2, Supplementary Table 5, Supplemen-
tary Figs. 3 and 4). The lowest LD was between the two MECOM
variants (r2= 0.36 in European data and 0.12 in Kazakh data) but
the FGF5 and SH3B2 variant pairs were in strong LD (r2 > 0.8;
Supplementary Table 5).
We further compared the effect estimates of the 896 BP
variants16 on preeclampsia in our meta-analysis, with the effect
on non-pregnancy diastolic and systolic BP and hypertension
based on meta-analyses of Icelandic and UK Biobank (UKBB)
data (Supplementary Fig. 5). We found that the four preeclampsia
associated variants at MECOM, FGF5, ZNF831, and SH2B3 are
among the variants with the highest effect on all three BP traits,
particularly on diastolic BP (Supplementary Fig. 5).
The 892 BP variants that did not individually show significant
association with preeclampsia, did, however, show concordance
of the preeclampsia risk allele with higher BP allele in meta-
analyses of European mothers (588 variants concordant, binomial
test P < 1.2 × 10−21), Central Asian mothers (504 variants
concordant, binomial test P < 2.9 × 10−5) and in European and
Central Asian mothers combined (591 variants concordant,
binomial test P < 1.1 × 10−22) (Supplementary Table 6 and see
“Methods” section).
Effect of maternal and fetal genomes. Through analyses of fetal
and maternal genomes, we have identified independent loci that
associate with preeclampsia. Since mother and fetus share half
their genomes, any variant that associates with preeclampsia only
through the fetus is expected to show half the effect in the mother
and vice versa. In our previous study, we showed that the fre-
quency of the risk allele of the index variant at the fetal FLT1
locus in affected mothers was halfway between that in the off-
spring and controls6. We further showed that the effect of the
variant was limited to the fetal genome, with no independent
effect of the maternal variant.
In the current meta-analyses, we see an effect of associated
variants in both maternal and fetal genomes (Supplementary
Table 7). We again disentangle the maternal and fetal effects
using EMIM17 (estimation of maternal, imprinting, and
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Fig. 1 Manhattan plots of genome-wide association results from the preeclampsia meta-analyses. P-values (−log10) from the meta-analysis are plotted
against their respective positions on each chromosome. a Offspring of preeclamptic pregnancies from Europe and Central Asia (6775 cases and 375,372
controls). b Preeclamptic women from Europe and Central Asia (9515 cases and 157,719 controls).
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interaction effects using multinomial modeling; see “Methods”
section and Supplementary Note 2). We performed EMIM
analysis on the sentinel variants at each of the five maternal loci
using genotypes of trios and mother-baby duos that were
available in two of the contributing studies. We found no
independent effect of the fetal genome for any of the variants after
accounting for the maternal genome. With the exception of the
ZNF831 variant rs259983, the association was significant for each
maternal variant after accounting for the fetal effect (Supple-
mentary Data 4).
Preeclampsia stratified by onset. Early-onset preeclampsia, often
clinically defined as onset before 34 weeks gestation, is associated
with more severe maternal and fetal complications. We therefore
tested the association of our lead maternal and fetal variants with
preeclampsia stratified by gestation at diagnosis of disease in four
European data sets of 1797 and 3757 early and late-onset
maternal cases and 800 and 2660 early and late-onset offspring,
respectively (Supplementary Table 8). Consistent with our pre-
vious report6, the effect of the fetal FLT1 variant rs4769612 was
mostly seen in late-onset cases, with a significant difference
between early and late-onset cases in a case/case analysis
(P= 0.014, Table 3). For one of the maternal discovery variants,
rs10774624 near SH2B3, the effect in early-onset cases was larger
than in late-onset cases (P= 0.016) (Table 3). For the other four
maternal variants, the effect size was not different (Table 3).
Effect on birth weight. Preeclampsia is frequently associated with
fetal growth restriction and low birth weight. We therefore made
use of the large UKBB data set, which includes self-reported birth
weight, to assess the effect of the variants on birth weight,
regardless of preeclampsia status. The fetal preeclampsia FLT1
variant was tested using the individual’s own birth weight
(N= 236,507) while the maternal preeclampsia variants were
tested using the reported birth weight of the female participant’s
first child (N= 178,241). The fetal FLT1 variant was associated
with lower birth weight (P= 2.6 × 10−3, Table 3) and two of the
maternal risk variants rs1918975 at MECOM and rs10774624 at
SH2B3 associated with lower birth weight of first child with
P= 1.9 × 10−4 and P= 4.5 × 10−22, respectively (Table 3). The
BP locus at SH2B3 has been shown to associate with maternal
effect on birth weight18, and consistent with our data the BP
raising allele associated with lower birth weight. In contrast, we
find no evidence in this population data set for the association of
the FGF5, ZNF831, and FTO loci with the birth weight of
first child.
Heritability of preeclampsia. We made use of the genetic data to
study the heritability of preeclampsia. We applied GCTA Geno-
mic Relatedness Restricted Maximum Likelihood (GREML)
analysis to the chip genotypes of European and Central Asian
subjects to estimate the SNP heritability of preeclampsia on the
liability scale19 (see “Methods” section). For Europe, we found the
heritability for maternal preeclampsia to be 38.1% (95% CI:
29.3–46.8) and in fetal preeclampsia 21.3% (95% CI: 7.4–35.3); for
Central Asia, the heritability was found to be 54.4% (95% CI:
29.6–79.3) and 42.5% (95% CI 17.3–67.7) for maternal and fetal
preeclampsia, respectively (Supplementary Table 9). These results
are consistent with those previously reported in European family-
based studies5.
Gestational hypertension. Gestational hypertension is defined as
new-onset hypertension at or after 20 weeks gestation in the
absence of proteinuria. This condition is not commonly asso-
ciated with maternal and perinatal mortality, although it is linked T
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to lower birth weight and subsequent maternal cardiovascular
disease. We explored the relationship between gestational
hypertension and the individual variants that we showed are
associated with preeclampsia, by testing their association in small
data sets of 4275 offspring and 3428 maternal cases from preg-
nancies diagnosed with gestational hypertension (Supplementary
Table 1). The risk allele of the FLT1 variant did not associate with
increased risk in gestational hypertension offspring (P= 0.21)
(Supplementary Table 10). The maternal variants at FTO and
SH2B3 both associated with gestational hypertension in maternal
cases with P= 1.7 × 10−3 and 3.7 × 10−5, respectively, while the
other preeclampsia variants did not associate with gestational
hypertension (Supplementary Table 10). However, all five
maternal preeclampsia variants had the same risk allele as the
gestational hypertension maternal variant. As these risk
alleles also increase BP, we looked at the other 892 BP variants,
previously analyzed for preeclampsia, and found excess of
concordance between BP-increasing alleles and gestational
hypertension risk alleles (564 variants concordant, binomial
test P < 5 × 10−16) (Supplementary Table 6 and see “Methods”
section).
Genetic overlap with other traits. In addition to hypertension,
epidemiological evidence indicates a shared risk between pre-
eclampsia and several vascular, metabolic, and inflammatory
traits20–23. Using the cross-trait LD-score regression method24,25,
we estimated the genetic correlation between preeclampsia, based
on the maternal meta-analysis, and a selection of 12 relevant traits
in deCODE and UKBB data (see Methods). We found a positive
genetic correlation between preeclampsia and both systolic and
diastolic BP, hypertension, CAD and T2D and a negative corre-
lation with birth weight of first child (Fig. 2 and Supplementary
Table 11).
Genetic correlation between preeclampsia and BP is expected
and in line with our finding of BP variants associating with
preeclampsia. Correlation between preeclampsia and the risk of
developing T2D has been noted previously and is consistent with
the association between preeclampsia and gestational diabetes26.
In our data, the genetic correlation of preeclampsia with T2D is
second only to its correlation with hypertension and BP.
We used a polygenic risk score (PRS) analysis to explore further
the correlation between preeclampsia and hypertension, T2D,
CAD, BMI, and birth weight. To avoid confounding by population
structure, we extracted risk alleles, P-values and effect estimates
for each trait from studies that did not include Icelandic subjects
and used these to calculate a standardized PRS for the Icelandic
preeclampsia data set. Consistent with the results from the genetic
correlation analysis the PRS for hypertension showed the most
significant association with preeclampsia (P= 1.2 × 10−12, effect
(loge odds ratio (OR))= 0.18, 95% CI: 0.13–0.23) (Supplementary
Table 12); the effect corresponds to the increase in the risk of
preeclampsia per standard deviation in PRS. The PRSs for T2D,
BMI and CAD also associated with preeclampsia (Supplementary
Table 12). Notably, when we adjusted the T2D, BMI and CAD
PRSs for the HT-PRS they were no longer significant, indicating
that this association was at least partly due to the increased risk of
hypertension implicit in those risk scores (Supplementary
Table 12). The PRS for higher birth weight of first child associated
with lower risk of preeclampsia and conditioning on the HT-PRS
had little effect on this association (Supplementary Table 12)
indicating that factors other than hypertension account for the
association between birth weight and preeclampsia. We further
tested the same risk scores on the Icelandic gestational hyperten-
sion data set (Supplementary Table 1). As for preeclampsia, the
strongest result was obtained for the HT-PRS (P= 2.1 × 10−35),
but the effect on gestational hypertension was nearly double that
on preeclampsia (loge OR= 0.32, 95% CI: 0.27–0.38) (Supple-
mentary Table 12).
Hypertension and preeclampsia in Europe and Central Asia.
Deciphering the relationship between preeclampsia and hyper-
tensive disease in pregnancy is of importance to increase our
understanding of the causes of preeclampsia. To further explore
this relationship, we compared the effects of HT-PRS on three
hypertension-related traits, preeclampsia, gestational hyperten-
sion, and essential hypertension in females, within the Icelandic
population. In these analyses, we restricted the control group to
females who had not been diagnosed with hypertensive disorders.
The risk score was associated with all three traits (Fig. 3). We note
that the removal of hypertensive women from the control group
increased the effect of the association between the HT-PRS and
preeclampsia (log-odds = 0.18, 95% CI: 0.13–0.23, see Supple-
mentary Table 12, to log-odds = 0.23, 95% CI: 0.19–0.28, Fig. 3).
Of note, the effect of the PRS on gestational hypertension was
similar to the effect on hypertension and around 1.7-fold higher
than the effect on preeclampsia (Fig. 3). Furthermore, the HT-
PRS explained 2.4% of the variance in hypertension and only
0.67% of the variance in preeclampsia (Fig. 3). The corresponding
genetic risk score based on the five variants discovered here to
associate with preeclampsia through the maternal genome only
explains 0.25% of the variance in preeclampsia (P= 1.6 × 10−8).
The effects of HT-PRS on preeclampsia in two additional Eur-
opean preeclampsia data sets (FINRISK and MoBa) and in the
two Central Asian data sets were comparable to the deCODE set
(Fig. 3).
Discussion
We present here a large-scale meta-analysis of maternal pre-
eclampsia as well as an expansion of our previous study of the
contribution of the fetal genome to preeclampsia. In addition to
European data sets, we also include data from Central Asian
populations, previously under-represented in human genetic
studies. To facilitate the use of Central Asian subjects in asso-
ciation analysis, we generated a haplotype reference panel based
on whole-genome sequencing of individuals from Kazakhstan
and Uzbekistan.
Even though we more than doubled the number of cases from
our previous meta-analysis of preeclampsia offspring6 the only
significant locus remained the previously reported FLT1 locus.
These additional data, however, allowed us to improve the fine
mapping of the locus, revealing a third independent signal. The
lack of evidence for more loci indicates that any additional var-
iants that associate with preeclampsia through the fetal genome
are likely to have less effect and/or lower minor allele frequency
and thus they require larger data sets for detection of association
(Supplementary Fig. 2).
This study identifies five maternal sequence variants that
associate with development of preeclampsia. While only two loci
were genome-wide significant in our meta-analysis, three addi-
tional loci were identified as significantly associated with pre-
eclampsia through analysis of variants associated with BP. Four of
the associated variants are among the strongest BP signals found
in a recent meta-analysis of BP traits16 and the fifth, the FTO
variant, is the variant that most strongly associates with BMI in
addition to its effect on BP13,14. The results of the PRS analysis
suggest that the effect of genetic predisposition to BMI on the risk
of preeclampsia is mostly through the effect of BMI on BP. This is
in contrast to the effect of the FTO variant on preeclampsia,
which is disproportionate to its effect on BP.
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A significant association between HT-PRS and preeclampsia
shows that genetic predisposition to hypertension is a major risk
factor for preeclampsia. However, it is interesting that whilst the
effect of the association with gestational hypertension coincides
with the association with hypertension, the effect on preeclampsia
is somewhat lower. While these results show an overlap in genetic
susceptibility to these two hypertensive disorders of pregnancy
they also highlight important differences. In particular, they
imply that, although genetic predisposition to hypertension
contributes significantly to the risk of preeclampsia, additional
factors are involved.
Although the effect estimates of the hypertension PRS were
derived from a European data set, association with preeclampsia
is similar in the European and Central Asian data indicating that
the risk score is measuring the same underlying risk in both
populations.
Women with hypertensive pregnancy disorders including
preeclampsia have significantly increased risk of future cardio-
vascular disease27–29. Potential explanations include common risk
factors in addition to the vascular damage sustained by the
hypertensive episode during pregnancy. Our data show that
preeclamptic women have an underlying predisposition to higher
BP, which helps explain the risk of cardiovascular disease. Any
role of endothelial dysfunction due to circulating inflammatory
and anti-angiogenic factors in pregnancy in the causality of future
cardiovascular disease remains undetermined. Importantly, our
data affirm the diagnosis of hypertensive disease in pregnancy as
predictors of future cardiovascular risk in women.
Given the results of the current study, it is likely that a large
number of sequence variants together affect the genetic predis-
position to preeclampsia, each contributing a small effect through
regulation of BP and probably, through other pathways. Such
factors could act either through the maternal or fetal genome or
both. Revealing those variants will require much larger studies
than this current meta-analysis. Importantly, in order to disen-
tangle the maternal and fetal contribution, both mother and child
need to be included in future studies of preeclampsia, as high-
lighted by the FLT1 locus that is among the most significant
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Fig. 2 Genetic correlation between maternal preeclampsia and selected traits. Genetic correlation between pairs of traits using the cross-trait LD-score
regression method in the European maternal preeclampsia data sets and the summary statistics from deCODE and UK Biobank data sets for each
secondary trait. On one hand, we calculated the genetic correlation between preeclampsia meta-analysis of GOPEC, ALSPAC, and MoBa data, and deCODE
GWAS summary statistic for each secondary trait, and on the other hand between preeclampsia meta-analysis of deCODE, SSI, and FINRISK data, and UK
Biobank GWAS summary statistic for each secondary trait. The P-values and genetic correlation estimates presented are the meta-analysis of the two
independent tests, with the exception of birth weight of first child where the results only include the preeclampsia meta-analysis excluding UK data sets
and the UK biobank data on birth weight of the first child. The height of the bars indicates the genetic correlation, blue bars indicate a positive correlation,
red bars indicate a negative correlation. Error bars indicate standard error. Red asterisks indicate results that are significant after accounting for the 12 traits
tested. Significance threshold: P = 0.05/12 = 0.0042. Details of the results presented in the figure are reported in Supplementary Table 11.
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signals in our maternal association study even though its effect on
susceptibility arises only from the fetal genome.
Methods
Participants, genotyping, imputation, and association analysis. The combined
fetal meta-analysis included eight data sets with a total of 6775 cases and 375,372
controls. The combined maternal meta-analysis included 9515 cases and 157,719
controls. Both studies were based on subjects of Northern European and Central
Asian origin. A further 2300 maternal cases and 5325 controls were used to follow-up
variants with a suggestive association (P < 1 × 10−6) in the meta-analysis. An over-
view of the data sets is shown in Supplementary Table 1 and an overview of clinical
details for each data set is reported in Supplementary Table 13. Written informed
consent for genetic studies was obtained from participants, or from parents on behalf
of minors, and all studies were approved by local Research Ethics Committees.
The GOPEC cohort comprises 1875 white western European women with
preeclampsia and 1004 offspring recruited in the UK for a number of genetic
studies of preeclampsia conducted between 1989 and 2010. 72% of women were
recruited at diagnosis30,31, 11% were recruited prospectively from pregnancy
cohorts32, and 17% were identified from the Aberdeen Maternity and Neonatal
Databank33. Women affected by preeclampsia were selected for this study based on
an internationally recognized definition34: new-onset hypertension after the 20th
week of gestation, with systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg on at
least two occasions; and new-onset proteinuria of 0.3 g/24 h or more, or ≥1+ on
dipstick analysis of urine. All were singleton pregnancies. Exclusion criteria
included pregnancies in women with a previous history of essential hypertension,
type 1 or type 2 diabetes or chronic renal disease.
All subjects provided a sample of venous blood for DNA extraction. Offspring
from preeclamptic pregnancies were available from two cohorts recruited at
diagnosis; DNA was extracted from the umbilical cord or capillary blood spots
obtained for neonatal screening.
Control data were derived from the WTCCC2 genome-wide analysis of
2930 samples from the 1958 Birth Cohort and 2737 samples from the National
Blood Services, providing control data for 5297 individuals after quality control
(QC)35. Details of genotyping and imputation of the cases and controls have been
reported6,36 and the number of subjects included in each analysis is shown in
Supplementary Table 1. The study was approved by the Derbyshire Research Ethics
Committee.
The deCODE preeclampsia cohort is a part of an ongoing sample collection
including a large fraction of the Icelandic population6. Briefly, singleton affected
pregnancies were identified through the scrutiny of hospital records from 1970 to
2017 at Landspitali University Hospital in Reykjavik. Records from 1999 and
earlier were examined and each affected pregnancy reclassified while pregnancies
from 2000 to 2017 were identified based on ICD-10 codes O14; O15 for
preeclampsia and O13 for gestational hypertension. Further data on each
pregnancy, including gestational duration at diagnosis of preeclampsia and BMI,
were obtained directly from maternity records. Genotyping and imputation
methods in the Icelandic samples were essentially as described previously37,38. In
short, we sequenced the whole genomes of 15,220 Icelanders using Illumina
technology to a mean depth of at least 10× (median 32×). SNPs and insertions and
deletions (indels) were identified and their genotypes called using joint calling with
the Genome Analysis Toolkit HaplotypeCaller (GATK version 3.4.07)39.
Information about haplotype sharing was used to improve genotype calls, taking
advantage of the fact that all of the sequenced individuals had also been chip-typed
and long-range phased. The 33.4 million variants that passed the high-quality
threshold were then imputed into 151,677 Icelanders who had been genotyped with
various Illumina SNP chips and their genotypes phased using long-range
phasing40. We further increased the sample size for association analysis and thus
the power to detect associations by imputing the sequence variants into 282,894
un-typed relatives of the chip-typed individuals using genealogic information. This
data set includes the maternal preeclampsia cases and their offspring as well as the
age-, sex-, and county-of-origin-matched controls. The control group comprised
individuals recruited through different genetic research projects at deCODE. Out of
2389 maternal cases included in the analysis, 1662 were chip-typed and 435 of the
2221 offspring included in the analysis were chip-typed. All of the variants that
were tested had imputation information above 0.8. To account for inflation in test
statistics due to cryptic relatedness and stratification, we applied the method of LD-
score regression24. With a set of 1.1 million variants, we regressed the χ2 statistics
from our GWAS scan against the LD-score and used the intercept as a correction
factor. LD scores were downloaded from an LD-score database (ftp://atguftp.mgh.
harvard.edu/brendan/1k_eur_r2_hm3snps_se_weights.RDS; accessed 23 June
2015). The estimated inflation factors based on LD-score regression were 1.08 for
maternal preeclampsia and 1.14 for the offspring analysis. The study was approved
by the Icelandic National Bioethics Committee (VSN-14-174). Written informed
consent was obtained from all genotyped subjects.
ALSPAC (Avon Longitudinal Study of Parents and Children) is a prospective
birth cohort study, which recruited 15,454 pregnant women with expected delivery
dates between 1st April 1991 and 31st December 1992 living in and around the city
of Bristol in the South West of England. There was a total of 15,589 fetuses. Of
these 14,901 were alive at 1 year of age. The study has been described in full
elsewhere41,42. Obstetric data, including all measurements of BP (median number
12; IQR: 11–16) and of proteinuria (12; 9–14) were extracted from obstetric records
by one of six trained midwives. Gestational hypertension was defined as systolic
BP ≥ 140 mmHg OR diastolic BP ≥ 90 mmHg on at least two occasions after
20 weeks of gestation in women who had not previously been diagnosed with
hypertension outside of pregnancy. Preeclampsia was defined as hypertension as
described for gestational hypertension accompanied by at least 1+ proteinuria on
dipstick testing (Albustix; Ames Co, Elkhart, Ind.) occurring at the same time as
the episodes of raised BP. The comparison (control) group were all other included
women or offspring with GWAS data who were not affected by hypertension
during pregnancy.
A total of 9912 ALSPAC children were genotyped using the Illumina
HumanHap550 quad genome-wide SNP genotyping platform6. ALSPAC mothers
were genotyped using the Illumina human660W-quad array at Centre National de
Génotypage (CNG) and genotypes were called with Illumina GenomeStudio.
Details of genotyping and quality control can be found elsewhere43. Haplotype
phasing was performed using ShapeIT (v2.r644) and known autosomal variants
were imputed with Impute V2.2.2 using the 1000 genomes reference panel (Phase
1, Version 3) consisting of 2186 reference haplotypes (including non-Europeans).
All imputed dosages converted to best guess genotypes in binary plink format,
Study
deCODE
Hypertension
Gestational hypertension
Preeclampsia
MoBa
Preeclampsia
FINRISK
Preeclampsia
Kazakhstan
Preeclampsia
Uzbekistan
Preeclampsia
META preeclampsia
Cases
21,677
1532
1662
1386
400
923
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5,181
Controls
50,943
50,943
50,943
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7,805
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61,426
Effect
0.37
0.39
0.23
0.27
0.19
0.27
0.17
0.23
95% CI
(0.35–0.39)
(0.34–0.45)
(0.19–0.28)
(0.19–0.36)
(0.096–0.29)
(0.17–0.36)
(0.08–0.27)
(0.200.27)
Pvalue
1 × 10−300
9.4 × 10−50
1.2 × 10−20
1.6 × 10−10
2.6 × 10−4
8.8 × 10−8
4.9 × 10−4
1.1 × 1040
R 2
0.024
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0.0067
0.024
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Effect (95% CI)
Fig. 3 Polygenic risk score analysis using PRS for hypertension. PRS effect estimates were based on GWAS analysis of the UKBB hypertension data set.
The top panel shows association between the HT-PRS and hypertension (females only), gestational hypertension and preeclampsia in genotyped subjects
from the deCODE cohort. The control group comprises females that are not on any of the case lists (hypertension-free controls). For other studies, the
association analysis used the preeclampsia cases and controls that were included in the respective maternal GWAS analyses. Effect reported as log-odds
corresponds to the increase in risk of the respective trait for one standard deviation of the hypertension risk score. 95% CI: 95% confidence interval.
P-values are obtained from logistic regression of case status on individuals’ polygenic risk score, adjusted for covariates (see “Methods” section). All
P-values are two-sided. R2 denotes the explained variance.
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using a hard call threshold of 0.1. Cases and controls for gestational hypertension
analysis were imputed with phased haplotypes from the Haplotype Reference
Consortium (HRC) panel. Ethical approval was obtained from the ALSPAC Ethics
and Law Committee and the Local Research Ethics Committees. Please note that
the study website contains details of all the data that is available through a fully
searchable data dictionary and variable search tool (http://www.bristol.ac.uk/
alspac/researchers/our-data/).
The Norwegian MoBa (Mother, Father and Child Cohort Study) is a
longitudinal study of over 110,000 pregnant women, their children and partners,
recruited between 1999 and 2008 from maternity units throughout Norway, and
has been described previously44. DNA was extracted manually from whole blood
samples obtained at recruitment (around 18 gestational weeks) using the FlexiGene
kit (Qiagen, Hilden, Germany). Birth outcome information for all MoBa
participants is obtained through linkage with the Medical Birth Registry of Norway
(MBRN)45. In the MoBa Preeclampsia case–control study, all preeclampsia cases
identified through linkage with the MBRN, and a subset of pregnancies unaffected
by preeclampsia, were validated using antenatal records and hospital discharge
codes46. Preeclampsia was defined using American College of Obstetrics and
Gynecologists criteria47. We included, from among these validated records, women
with a singleton pregnancy who conceived spontaneously, were verified cases or
controls, returned both early and late pregnancy study questionnaires, had blood
stored in the MoBa biobank, and had no history of chronic hypertension: 1564
validated preeclampsia cases (1118 had both mother and child DNA, and 446 had
only maternal DNA) and 999 controls (of which 968 had a mother and child DNA,
and 31 had only maternal DNA). The date of onset was defined as the first
gestational week when both blood pressure and proteinuria criteria were
simultaneously noted in the antenatal chart. Mothers were genotyped by the UNC
Mammalian Genotyping Core using the HumanCoreExome-12 Bead Chip from
Illumina (Illumina, Inc., San Diego, CA). Samples and SNPs were examined using
PLINK 1.07 for quality control. SNPs were excluded if the missing rate exceeded
5%, there was a substantial deviation from HWE (P < 1×10−3) or the MAF was
<0.125. For each pair of related mothers, we preferentially included the one with
the most complete genetic data, or in the case of equivalence, randomly sampled
between them. Quantile-quantile plots and calculation of genomic control lambda
(λGC= 1.01) indicated no systematic test statistic inflation, unidentified
relationships, or cryptic admixture. Outliers for any of the first three 1000
Genomes axes of variation (based on CEU, YRI, CHB, PUR, CLM, and MXL) >
3 standard deviations from the mean were excluded. The post-QC data set was
imputed using PBWT and pre-phased using SHAPEIT2 against the 1000 Genomes
Phase 3 reference panel. Imputation for GWAS analysis was conducted by the
Sanger Imputation Service provided by the Wellcome Trust Sanger Institute. Data
used for the analysis of disease onset and PRS was imputed at deCODE genetics
using the same reference panel. The study was approved by the Regional
Committee for Medical Research, South East Norway.
SSI (Statens Serum Institut) Danish study subjects were drawn from a
case–control study of severe, early-onset preeclampsia and were all of Scandinavian
(Danish, Faroese, Norwegian, Swedish, or Icelandic) ancestry. Severe preeclampsia
cases were identified through the Danish National Patient Register, which includes
all hospital diagnoses assigned since 197748, using the ICD-8 code 637.04 and the
ICD-10 codes O14.1, O14.2, and O15.0–15.9. Timing of onset was defined based on
gestational age at delivery. Women were classified as having had early preterm
preeclampsia if they delivered before 34 completed weeks of pregnancy and late
preterm preeclampsia if they delivered between 34 and 36 completed weeks of
pregnancy. Controls for the maternal analysis were randomly selected from among
parous women without cardiovascular disease, diabetes or kidney disease and with
a history of only healthy pregnancies ending in live births at 40 weeks’ gestation,
and were matched 1:1 to the case women on maternal birth year and age at first
delivery. Fetal cases were singletons from preeclamptic pregnancies of a subset of
cases from the maternal analysis and controls were individuals genotyped with the
same array (Illumina Multi-Ethnic Global v2 A2 at SSI). Biological samples were
drawn from the Danish Neonatal Screening Biobank49 and the biobank of the
Danish National Birth Cohort50, both of which are part of the Danish National
Biobank. This study was approved by the Scientific Ethics Committee of the Danish
Capital City Region (Copenhagen) (approval no. H-6-2013-008) and the Danish
Data Protection Agency (approval no. 2015-57-0102). The Danish Scientific Ethics
Committee granted an exemption from obtaining informed consent from study
participants as this research project was based on existing biological samples
already held in a biobank. All SSI samples were genotyped using the Illumina
Multi-Ethnic Global v2 A2 array. Data cleaning and quality control were
performed using a sequential procedure. After the quality control steps, we ended
up with 872 cases and 815 controls for the maternal analysis and 213 cases and 963
controls for the fetal analysis. After genotyping QC, we imputed unobserved
genotypes with phased haplotypes from the HRC panel (version r1.0). Association
analysis of imputed autosomal SNPs with preeclampsia was performed using
logistic regression on imputed SNP dosages that had an imputation info score ≥ 0.8
and MAF > 1%, under an additive genetic model using PLINK51.
FINRISK is a series of health examination surveys carried out by the National
Institute for Health and Welfare of Finland every 5 years in 1972–2012 and has
been described previously52. The surveys are based on random population samples
from five (six in 2002) geographical regions of Finland. The age-range was 25 to 64
years until 1992 and 25 to 74 years since 1997. The survey includes a self-
administered questionnaire, a standardized clinical examination carried out by
specifically trained study nurses and the collection of a blood sample for laboratory
measurements and DNA extraction53. We chose 402 women with a history of
preeclampsia and 7924 female controls with normal delivery from the 1992, 1997,
2002, 2007, and 2012 FINRISK surveys. For identifying preeclamptic and eclamptic
women, we used the following Finnish International Classification of Disease (ICD)
codes in the comprehensive National Hospital Discharge Register covering years
1992 to 2007: ICD-10 (in use since 1996): O14.0, O14.1, O14.9, O15.0, O15.1,
O15.2, O15.9; ICD-9 (in use from 1987 to 1996): 6424 to 6426, 6427A; and ICD-8
(in use from 1968 to 1986): 637.03, 637.04, 637.09, 637.10, 637.99. The FINRISK
samples were genotyped using multiple different genotyping chips, for which the
QC, phasing, and imputation were done in multiple chip-wise batches. Principal
component (PC) analysis was applied to detect population structures and outliers
removed. Imputation was done utilizing a population-specific reference panel
(http://www.sisuproject.fi) of 2690 high-coverage whole-genome and 5,093 high-
coverage whole-exome sequences with IMPUTE254. The FINRISK study was
approved by the Helsinki University Hospital ethical committee.
Central Asian subjects of Uzbek and Kazakh ancestry, determined by
grandparental ethnicity, were recruited between 2012 and 2015 from six maternity
units in Uzbekistan and seven in Kazakhstan. Women with singleton pregnancies
affected by preeclampsia were recruited at the time of diagnosis; healthy pregnant
controls were recruited from the same maternity centers. The diagnostic criteria for
preeclampsia were: systolic BP≥ 140mmHg and diastolic BP ≥ 90mmHg on at least
two occasions within 24 h after the 20th week of pregnancy in a previously
normotensive woman, accompanied by proteinuria ≥300mg/L. Women below the
age of 18, those with a prior history of hypertension, non-infective renal disease, type
1 or type 2 diabetes, or 3 or more consecutive miscarriages, were excluded. Volunteers
provided a sample of venous blood for DNA extraction. DNA from the offspring of
preeclamptic pregnancies was extracted from a sample of umbilical venous blood or
umbilical cord obtained at delivery. All volunteers gave informed consent for
participation in the study; mothers gave consent on behalf of their offspring.
Three batches of Kazakh preeclamptic mothers, babies, and control sets were
genotyped at the deCODE genotyping facility using Illumina SNP genotyping
platforms. Kazakh 1, including 1003 sets was genotyped on Illumina 2.5-8, Kazakh
2, including 761 set, on OmniExpress, and finally Kazakh 3, including 772 sets, on
Infinium GSA. We carried out quality control analysis using PLINK (http://zzz.
bwh.harvard.edu/plink/), SMARTPCA (https://www.hsph.harvard.edu/alkes-price/
software/Eigensoft) and Admixture (http://dalexander.github.io/admixture/).
For each batch variants with call rate <95% and Hardy–Weinberg equilibrium
P < 1 × 10−6 were excluded. QC tests on the genotyped samples included yield,
parent–child relationship and gender test. Samples with call rate <95% were
excluded from the study. Duplicate samples were excluded except where the
parent–child relationship confirmed the correct identity of the sample. Male
samples from maternal and control groups as well as all samples in the control
group with a genotyped first-degree relative were excluded. In order to account for
population structure, we applied PC analysis and excluded population outliers from
the study. PC analysis was performed separately on each association data set. The
final number of samples included in each analysis is shown in Supplementary
Table 1. Over 70% of the original samples were included. Exclusion of population
outliers removed 10% of the samples, mostly due to exclusion of 28% of all control
samples.
For each of the three batches, maternal and fetal case–control sets were
separately imputed using IMPUTE2. The reference panel consisted of a Central
Asian whole-genome sequence panel (see Supplementary Note 1) merged with
1000 genomes Phase 3 haplotype reference panel. The Ministry of Health, Republic
of Kazakhstan, Central Ethics Committee gave approval for the conduct of
the study.
2869 samples from Uzbek preeclamptic mothers, their offspring, and controls
were genotyped on the Omni 2.5-8 chip. The genotypes were called using Gencall
genotype calling algorithm. Quality control measures included gender and
relatedness checks, and samples with call rates <95% or heterozygosity >± 3 SD
were excluded, resulting in the retention of 2742 samples. The quality of the calls
for individual variants was assessed by looking at founder individuals (mothers and
controls). The following QC filters were applied to autosomal SNPs using the plink
software (version 1.90b downloaded from www.cog-genomics.org/plink2):
violation of Hardy–Weinberg Equilibrium; haplotype-based test for non-random
missing data, Bonferroni corrected P < 0.05; call rate <98%. A total of 2,292,786
autosomal variants were genotyped. The quality control procedure identified
50,793 poorly genotyped SNPs leaving 2,241,993 SNPs available for further
analysis.
The GWAS samples were pre-phased using SHAPEIT and then imputed using
IMPUTE2. The Uzbek samples were imputed using the reference panel described
for imputation of Kazakh samples, constructed from a Central Asian whole-
genome sequencing panel merged with 1000 Genomes Phase 3. We filtered the
imputed variants by requiring that the info >0.8. In total, >11 million imputed and
genotyped variants were available for further analysis. The study was approved by
the National Ethics Committee, Ministry of Health, Republic of Uzbekistan.
Association analysis. Logistic regression was used to test for association between
variants and disease, assuming an additive model, treating disease status as the
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response and expected genotype counts from imputation as covariates. For the
deCODE cohort, information on the county of origin within Iceland were included
as covariates to adjust for possible population stratification. This was done using
software developed at deCODE genetics37. For the SSI cohort association, analysis
was done using PLINK. GOPEC, ALSPAC, MoBa and Uzbek cohorts included the
top five ancestry principal components as covariates (SNPTEST (v2.4.1)). For the
FINRISK and Kazakh cohorts, the top twenty (FINRISK) and ten (Kazakhstan)
ancestry principal components were included as covariates (SNPTEST (v2.5))55.
Follow-up data sets. FINNPEC (Finnish Genetics of Preeclampsia Consortium):
The FINNPEC collection was assembled in Finland between 2008 and 2011 from
two recruitment arms and has been described previously56. Samples were collected
at the time of diagnosis of preeclampsia from 879 mothers and during pregnancy
from 922 non-preeclamptic mothers from antenatal and labor wards. Their chil-
dren and partners were also enrolled. A further 525 pregnancies affected by pre-
eclampsia were identified by examination of hospital records, and women and
offspring were invited to participate by letter. After exclusion of pregnancies that
did not meet the entry criteria for this study, 678 preeclamptic mothers and 580
offspring were included as cases, and 700 non-hypertensive mothers and 760
offspring provided the control group. Offspring genotype data included in this
study were generated in our previous study6. Samples were genotyped at the BHF
Glasgow Centre for Cardiovascular Research using an OpenArray platform, and at
the Wellcome Trust Sanger Institute using Sequenom technology. The Hospital
District of Helsinki and Uusimaa Co-ordinating Ethics Committee approved
the study.
DNBC (Danish National Birth Cohort): The Danish follow-up samples were
drawn from the DNBC, a population-based cohort of more than 100,000
pregnancies, recruited in the years 1996–2002, and have been described
previously50. Extensive phenotype information is available for the DNBC mothers
and children based on computer-assisted telephone interviews, questionnaire-based
follow-up surveys and data from the Danish population and health registers.
DNBC women with preeclampsia were identified from the Danish National Patient
Register48 using ICD-8 codes 63700-63719 and ICD-10 code groups O13.9, O14
and O15. Only singleton pregnancies were included. As controls, we used mothers
without any preeclampsia-related diagnosis codes in any pregnancy. The Scientific
Ethics Committee for the Capital City Region (Copenhagen) and the Danish Data
Protection Agency approved the study. The Scientific Ethics Committee also
granted exemption from obtaining informed consent from participants (H-B-2007-
124) as the study was based on biobank material. Follow-up variants were
genotyped using the Centaurus (Nanogen)57 or KASP (LGC Genomics) platform.
The HUNT study (HUNT) is an ongoing longitudinal health survey of the
population of Nord-Trøndelag County in Norway, including ~120,000
individuals58. DNA samples are available from ~70,000 subjects recruited to
HUNT2 and HUNT3, in 1995–1997 and 2006–2008, respectively. Women with a
history of preeclampsia were identified retrospectively by linking the HUNT
database to the Medical Birth Registry of Norway (MBRN), using diagnosis codes
ICD-8 (before 1998) and ICD-10 (after 1998). The MBRN defines preeclampsia as
an increase in BP to at least 140 systolic or 90 mmHg diastolic (or an increase in
diastolic BP ≥ 15 mmHg from the level measured before 20th gestational week),
combined with proteinuria (protein excretion of ≥0.3 g per 24 h or ≥1+ on
dipstick). These criteria are in accordance with the diagnostic criteria used
clinically in Norway until 2006. Of the HUNT participants, 1134 women with a
history of preeclampsia in one or more pregnancies were identified, and for 2/3 of
the women, the diagnosis had been validated by scrutiny of hospital records59. A
total of 2212 women with healthy, non-hypertensive pregnancies and a further
4000 women from the HUNT population provided the control group.
The HumanCoreExome-12 v1.0 (Illumina), HumanCoreExome-12 v1.1
(Illumina) and UM HUNT Biobank v1.0 was used to genotype ~600,000 variants.
Genotype calling was performed with Genome Studio (Illumina). Samples with
genotype call rates <99% were excluded, as were duplicates, samples with
contamination >2.5% as estimated with BAF Regress, and those with gender
mismatches or evidence of non-European ancestry from principal components
analysis (P < 0.0001). Variants were excluded if the cluster separation score was
<0.3, Gentrain score was >0.15, genotyping fail rate >1% or they deviated from
Hardy–Weinberg equilibrium (P < 1×10−4). Samples were phased with Eagle2
v2.360, and genotype imputation was conducted with Minimac3 (v2.0.1, http://
genome.sph.umich.edu/wiki/Minimac3)61 and a merged reference panel that was
constructed by combining the Haplotype Reference Consortium panel (release
version 1.1)62 and a local reference panel based on 2202 whole-genome sequenced
HUNT study participants.
Association with preeclampsia was tested using a generalized mixed model
including covariates birth year, sex, genotype batch, and principal components 1–4
as implemented in SAIGE. Principal components were computed using PLINK.
Additional filters applied to the analysis included minor allele count ≥10 and
imputation r2 ≥ 0.3. The study was approved by the Regional Committee for
Medical and Health Research Ethics, Central Norway.
UKBB data. The UKBB project is a large prospective cohort study of ~500,000
individuals from across the United Kingdom, aged between 40 and 69 at recruit-
ment63. Genotyping was performed using a custom-made Affymetrix chip, UK
BiLEVE Axiom87 in the first 50,000 participants, and with the Affymetrix UK
Biobank Axiom array in the remaining participants. 95% of the signals were on
both chips. Imputation was performed by Wellcome Trust Centre for Human
Genetics using a combination of the HRC, 1000 Genomes phase 3 and the UK10K
haplotype resources64. Association analysis was performed using software devel-
oped at deCODE genetics37. Information on UKBB traits used in the study is
included in Supplementary Table 14. UK Biobank’s scientific protocol and
operational procedures were reviewed and approved by the North West Research
Ethics Committee.
deCODE data. Information on secondary deCODE traits used is included in
Supplementary Table 14.
Meta-analysis. Variants were matched between data sets on the basis of position
(NCBI Genome Reference Consortium Build 37) and alleles. We included variants
that were well-imputed (info > 0.8), with a minor allele frequency >0.5% and
present in at least two data sets. This left 11,796,347 and 12,130,433 autosomal
variants for the maternal and fetal analysis, respectively.
The meta-analyses were conducted using the fixed-effects inverse-variance
method based on effect estimates and standard errors implemented in METAL65.
Genomic control correction was applied prior to meta-analysis, where appropriate,
using the genomic control option in METAL.
Conditional analysis. We applied approximate conditional analyses, implemented
in the GCTA software19, to the meta-analysis summary statistics to look for
additional association signals at each of the genome-wide significant loci. We
analyzed the European and Asian data sets separately, estimating LD between
variants using sets of 8700 whole-genome sequenced Icelandic individuals for the
European analysis and 1787 chip-typed Kazakh individuals for the Central Asian
analysis. The European and Central Asian results were then meta-analyzed. The
analysis was restricted to variants present in both the European and Asian data sets
and within 1 Mb from the index variants. We tested 7098 variants on one locus in
the fetal analysis and report two variants with conditional P-value < 7.0 ×10−6, and
11,844 variants at two loci in the maternal analysis with no variant reaching the
conditional P-value < 4.2 ×10−6.
Validation of imputation. One variant, rs139106685 on 6q14 showed suggestive
association in the Central Asian maternal meta-analysis (P= 4.02 × 10−8) (Sup-
plementary Fig. 1). This variant was absent in the European data. The minor allele
frequency of this variant is 0.028 in the Central Asian data and this prompted us to
check the imputation quality of the variant by direct genotyping of 4221 Kazakh
samples. Twelve out of 134 imputed carriers and three out of 4087 imputed non-
carriers carried the variant. The Central Asian data were imputed based on 1000
genomes phase 3 reference set complemented by a reference set based on whole-
genome sequencing of 200 Kazakhs and Uzbeks (Supplementary Note 1) and this
variant was not present in the Central Asian reference set. We thus conclude that
the association observed for this variant is an artifact of low-quality imputation.
Power calculation. We estimated OR for a given allelic frequency of a variant for
which we have 80% power to detect association using the estimated effective
number of cases and controls for the study. The effective number of cases, or
controls, was estimated for each cohort as neff= 2*na*nc/(na+ nc), where na, nc are
the number of cases and controls used. For the Icelandic cohort, the effective
sample size was further divided by the estimated genomic inflation factor, λg, to
adjust for relatedness of the cohort. The effective sample size for the study was then
calculated as the sum of neff for individual cohorts.
Functional annotation of FLT1 variants. Variants in LD with the lead variants
were identified based on whole-genome sequenced Icelandic individuals using
r2 > 0.8. These variants were then annotated by the intersection with chromatin
immunoprecipitation (ChIP-seq) and DNase hypersensitivity (DHS) data derived
from the ENCODE project (www.encodeproject.org). ChIP-seq data were down-
loaded in pre-processed (MACS v2 algorithm) bigWig format representing analysis
of acetylation of lysine K27 of histone H3 (H3K27ac) and mono-methylation of
lysine K4 of histone H3. The accession numbers used are listed out in Supple-
mentary Data 1. The ChIP-seq signal P-values were adjusted by the Benjamini-
Hochberg procedure to account for multiple hypotheses and thresholded at the 1%
FDR significance level. DNase hypersensitivity data (DHS) were downloaded in a
pre-processed format (Hotspot algorithm). We then made use of the Joint Effect of
Multiple Enhancers (JEME) resource to find enhancer-gene targets66.
Preeclampsia onset and birth weight. The association between fetal and maternal
discovery variants and disease onset was tested in combined GOPEC, deCODE,
MoBa, and SSI offspring and maternal data sets, respectively, where data on time of
diagnosis was available (Supplementary Table 8). The combined analysis included
800 early-onset and 2660 late-onset preeclampsia offspring and up to 378,185
controls. The combined maternal analysis included 1797 early-onset and 3757 late-
onset maternal cases and up to 144,355 controls. Early-onset was defined as
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diagnosis before 34 weeks gestation except in the SSI samples where early-onset
was defined as delivery before 34 weeks gestation. Association with birth weight
was tested in data from the UKBB. These data were not adjusted for the gestational
duration. We tested the effect of the fetal variant on self-reported own birth weight
(N= 236,507) and the effect of the maternal variants on reported weight of the first
child (N= 178,241). Birth weight data were inverse normal transformed and
adjusted for year of birth and the first 10 principal components. For the 6 variants
tested, the Bonferroni corrected level of significance is P= 0.05/6= 0.0083.
Concordance analysis. All five of the genome-wide significant maternal pre-
eclampsia variants were in strong LD with known variants associated with BP and
the preeclampsia risk allele (allele with higher frequency in preeclampsia cases
versus controls) was also the same allele known to be associated with higher BP at
sentinal SNPs of all five known BP loci. Therefore, we hypothesized that some or all
of the other 892 known BP variants listed in Supplementary Table 18 of Evangelou
et al.16 (the paper reports a total of 984 BP variants at 901 loci), may also exhibit a
positive correlation of the known higher BP allele and preeclampsia (or gestational
hypertension) risk allele identified in our meta-analyses. Under the null hypothesis
that such positive correlation does not exist at any of the 892 BP variants, the
probability of concordance of the preeclampsia (or gestational hypertension) risk
allele and higher BP allele at each variant is random and equals 0.5; and since the
892 variants are not in LD and hence are independent, the null hypothesis prob-
ability of total concordances at the 892 variants can be calculated with a binomial
distribution based on 892 binomial trials with 0.5 probability of trial success. To
calculate the tail probabilities of the binomial distribution, we used the pbinom
function implemented in R statistical software (www.r-project.org). The p-value of
this two-tail binomial test is extremely low for each meta-analysis (P < 2.9×10−5 to
P < 1.1×10−22) (Supplementary Table 6). Thus the null hypothesis can be rejected
and we conclude that the higher BP allele and preeclampsia (or gestational
hypertension) risk allele are positively correlated at some of the 892 known BP
variants.
For these analyses, the high BP allele at each of the 892 variants was taken from
the European results section of Supplementary Table 18 in Evangelou et al.16 and
the preeclampsia or gestational hypertension risk allele was the higher frequency
allele in cases compared to controls at each variant as observed in the GWAS meta-
analyses of European mothers, Central Asian mothers, or European-Central Asian
mothers combined. In Supplementary Table 6, the European maternal
preeclampsia analysis used all 892 SNPs since all the variants had been genotyped
in some of the 6 European maternal data sets; the Central Asian PE mothers
analysis used 883 of the 892 variants, one SNP was omitted due to its PE odds ratio
being 1.0 (and thus it had no PE risk allele) while 8 other variants with missing data
were omitted; the European and Central Asian PE mothers analysis used 891 of 892
variants and omitted one variant with PE odds ratio of 1.0; the European GH
mothers analysis used 888 of the 892 variants with one SNP omitted due to its GH
odds ratio being 1.0 while 3 other variants with missing data were omitted.
Separation of fetal and maternal effects. The family genotype data were jointly
analyzed across the GOPEC and MoBa cohorts using a modified version of the EMIM
method that allows for joint modeling across cohorts (Supplementary Note 2). EMIM
models the multiplicative increase in disease risk relative to the homozygous reference
genotype conferred by the presence of 1 or 2 risk alleles in the mother (S1 or S2) or the
offspring (R1 or R2). We considered a multiplicative effects model L(R1,S1) where
R2 ¼ R21 and S2 ¼ S22. We then used a likelihood ratio test to formally test the
significance of the full multiplicative effects model L(R1,S1) vs the models where the
association is explained purely by the fetal effect only; L(R1,S1= 1) and by the
maternal effect only L(R1,S1= 1). Both the likelihood ratio tests and confidence
intervals show (Supplementary Data 4) that we are unable to reject the maternal only
model at the 5% significance level for any of the 5 maternal loci, but conversely, we
are able to reject the fetal only model for 4 of the 5 maternal loci.
The genotyping of the MoBa cohort is as previously described6. For three
variants, rs259983, rs1421085, and rs10774624, follow-up data for the MoBa
samples were in silico data based on 1046 fetal cases, 1469 maternal cases and 961
controls assayed on the Illumina HumanCoreExome-12 v1.1 chip and imputed
based on the 1000 Genomes Project Phase 3 reference panel. Imputed variants are
hard called with a hard call threshold of 0.1.
LD-score regression. We estimated the genetic correlation between pairs of traits
using the cross-trait LD-score regression method24,25 in our meta-analysis and
summary statistics from traits in the deCODE and UKBB data sets. The traits
tested were: diastolic blood pressure, systolic blood pressure, hypertension, cor-
onary artery disease, ischemic stroke, venous thromboembolism, chronic kidney
disease, type 2 diabetes, body mass index, birth weight of the first child, asthma,
and rheumatoid arthritis. To avoid potential bias due to differences in LD structure
between Central Asian and European data this analysis included only the European
maternal meta-analysis. The sample size of the European offspring analysis was not
sufficient for this analysis. We used results for about 1.1 million variants (excluding
the MHC region), well-imputed in both data sets, and for LD information we used
pre-computed LD scores for European populations (downloaded from https://data.
broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2). To avoid bias due
to overlapping samples, we calculated the genetic correlation between a meta-
analysis of GOPEC, ALSPAC, and MoBa preeclampsia cohorts and the Icelandic
GWAS summary statistic for each secondary trait, and also between a meta-
analysis of deCODE, SSI and FINRISK preeclampsia cohorts and UKBB GWAS
summary statistic for each secondary trait. The results of the two analyses were
subsequently meta-analyzed. The birth weight analysis included included all Eur-
opean non-UK preeclampsia data sets and UKBB birth weight data. The sample
size for each secondary trait is reported in Supplementary Table 11.
We estimated observed scale SNP heritability with LD-score regression using
pre-computed LD scores for about 1.2 million variants found in European
populations (downloaded from: https://data.broadinstitute.org/alkesgroup/
LDSCORE/eur_w_ld_chr.tar.bz2) for an effective sample size of 10,255 maternal
and 7259 fetal cases in the European meta-analysis.
Heritability estimation. For each cohort, we applied GCTA (version 1.93.2)
separately to the maternal and fetal case–control post-QC and pre-imputation
genotypes. The genetic relatedness matrix was calculated on autosomal SNPs with
–grm-cutoff=0.05 and the first 10 principal components were included as fixed-
effects in the linear mixed model. The disease prevalence was set to 4%. The per-
region heritability was calculated by combining the per cohort estimated herit-
ability and standard error using fixed-effect inverse-variance meta-analysis. No
significant heterogeneity was observed (Phet > 0.1).
Polygenic risk score analysis. We used PRS analyses of the GWAS results for one
trait to investigate its predictive power for another trait. We used effect estimates
based on GWAS analysis in the UKBB data set for hypertension and birth weight,
and published meta-analysis for T2D67, BMI68, and CAD69. To avoid confounding
the association, the analysis was not done on the same populations as we are used
to deriving effect estimates.
The risk scores were calculated using genotypes for about 600,000 well-imputed
autosomal markers. We estimated LD between markers using 4000 phased
Icelandic samples and used this LD information to calculate adjusted effect
estimates using LDpred70. We created several PRSs assuming different fractions of
causal markers (the P parameter in LDpred), and selected the PRSs that best
predicted the trait itself. The fraction of causal markers used was: 30% for the PRSs
for hypertension and birth weight, 3% for the PRS for BMI, and 1% for the PRSs
for T2D and CAD. The correlation between the PRS and traits was calculated using
logistic regression in R (v3.5) (http://www.R-project.org) adjusting for principal
components by including them as covariates in the analysis.
When analyzing the association of PRS for different traits on deCODE sets of
preeclampsia and gestational hypertension the controls were the same as included
in the GWAS analysis (female subjects recruited through different genetic research
projects at deCODE, see description of deCODE data set above). For comparison of
hypertension risk scores between traits in Iceland, and between cohorts, for
consistency we excluded from the deCODE control group any individuals that were
cases in any of the three traits tested (hypertension, gestational hypertension,
preeclampsia), using the same, essentially hypertension-free, female control group
for all three traits. Similarly, we only used female hypertension cases in this
analysis.
We estimated the variance explained, r2, using the method of Nagelkerke71. The
reported variance explained is the estimated r2 value for the model including the
PRS and covariates, minus the r2 for the model only including covariates.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Meta-analyzed GWAS data used in this study as well as individual-level GWAS data
from the Uzbek and Kazakh studies and whole-genome sequencing data on Uzbek and
Kazakh subjects have been deposited in the European Genome-phenome Archive
(https://ega-archive.org) under accession numbers are as follows. Whole-Genome
Sequencing: EGAD00001005467, EGAD00001005466; Kazakhstan GWAS Genotypes:
EGAD00010001945, EGAD00010001949, EGAD00010001947; Uzbekistan GWAS
Genotypes: EGAD00010001917, EGAD00010001918, EGAD00010001919; GWAS Meta-
Analyses: EGAD00010001983, EGAD00010001984, EGAD00010001985,
EGAD00010001986, EGAD00010001987, EGAD00010001988. For pre-computed LD
scores for European populations, see https://data.broadinstitute.org/alkesgroup/
LDSCORE/eur_w_ld_chr.tar.bz2; for ENCODE project see www.encodeproject.org.
Code availability
All custom codes used in this study are freely available online.
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